Skip to main content
Premium Trial:

Request an Annual Quote

Polyplus-transfection Enters Reagent Deal with Roche Glycart

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Polyplus-transfection announced today it has granted a non-exclusive license to Roche Glycart for use of polyethylenimine for in vitro transfection applications for research purposes.

As a result, Roche Glycart will be able to use the transfection reagent to produce antibody-based products.

Based in Strasbourg, France, Polyplus-transfection is a privately held biotech firm that develops solutions for the in vivo, in vitro, an ex vivo delivery of nucleic acids for research, bioproduction, and therapeutic applications.

Roche Glycart is a Swiss biotechnology firm owed by Roche.

Terms of the deal were not disclosed.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.